Skip to main content
Premium Trial:

Request an Annual Quote

Castell to Retire from GE Healthcare; French Joins Sirna; Nanosphere Hires Shipp; Cash, Gene Codes Awarded Humanitarian Citation; and Others

Bill Castell, CEO of GE Healthcare, will retire next year. Castell's plans were included in an announcement last week about the realigning of GE's 11 business units into six industry-focused businesses: GE Infrastructure; GE Industrial; GE Commercial Financial Services; NBC Universal; GE Healthcare; and GE Consumer Finance.

 

Castell will remain the head of GE Healthcare and a member of the board of directors until his retirement, at which time Joe Hogan will take over as president and CEO of GE Healthcare. Hogan has served as president and CEO of the Waukesha-based GE Healthcare Technologies division, once known as GE Medical Systems, since 2000, when he succeeded Jeff Immelt. Immelt was promoted to succeed Jack Welch as head of GE.

 

The Sunday Times of London reported last weekend that Castell may take the reins of the Wellcome Trust when its current chairman, Sir Dominic Cadbury, retires. A Wellcome Trust spokesperson told GenomeWeb News that this report is "speculation," and that the UK-based medical research charity is still trying to "identify suitable people" to replace Cadbury.


Michael French has joined Sirna Therapeutics as senior vice president for corporate development. He will report to Sirna CEO Howard Robin. French most recently served as chief business officer at Entelos and has held business development positions at Farma Biagini and Bayer.


Nanosphere has hired Gregory Shipp as vice president of medical affairs, a new position at the company. Shipp's appointment comes as the firm prepares to launch its Verigene system for detecting DNA, RNA, and proteins on a single platform. Shipp was most recently medical director and chief medical officer for i-STAT, an Abbott point-of-care division. He also served as clinical affairs director for Boston Scientific Medi-tech, and as senior medical officer for Bio-Reg Associates.


The International Society for Computational Biology awarded a citation for "outstanding contributions to humanity" to Gene Codes at last week's annual Intelligent Systems for Molecular Biology conference in Detroit. CEO Howard Cash accepted the award on behalf of his staff. ISCB recognized the company for its role in identifying the victims of the WorldTradeCenterattacks in New Yorkon Sept. 11, 2001. Cash detailed the effort, which required his company to work around the clock to deliver weekly software updates, in the conference's opening keynote address. ISCB President Michael Gribskov called Gene Codes' contribution "unique, valuable, and beyond the limit of what could be expected."


Barbara Bryant of Millennium Pharmaceuticals, Shoba Ranganathan of MacquarieUniversity, David Rocke of the Universityof California-Davis, and Burkhard Rost of ColumbiaUniversityare running for president-elect of the International Society for Computational Biology. The president-elect serves a one-year term alongside the current ISCB president, Michael Gribskov, before taking over the presidency for the following two years. ISCB members will begin voting on August 15.


Frank White is joining Gene Codes as director of marketing. White was most recently program marketing manager at IBM Healthcare and Life Sciences. Prior to joining IBM, he served as director of business development at InforMax.


Eric Neumann has left his position as global head of knowledge management at Sanofi-Aventis to provide consulting services in the application of semantic web technologies to drug discovery. Neumann was previously VP of bioinformatics and knowledge research at Beyond Genomics. He has also held positions at 3rd Millennium, NetGenics, and Bolt, Beranek & Newman.


Peter Leddy has joined Invitrogen as senior vice president of human resources. He most recently served as vice president of human resources for the Americasoperations of Dell. Leddy will oversee Invitrogen's global HR strategy and report directly to CEO Greg Lucier.


Daniel Bradbury and John Stuelpnagel have been reelected to Illumina's board of directors, following the company's annual meeting of stockholders held in San Diegolast week. Bradbury serves as chief operating officer of Amylin Pharmaceuticals, and Stuelpnagel is senior vice president and COO of Illumina.


Thomas Hudson has been named to the scientific advisory board of Biopotential Capital, the Calgary, Alberta-based venture capital firm said June 14. Hudson is an associate professor and associate physician in the departments of medicine & human genetics at McGillUniversityand is the founder and director of the McGillUniversityand Genome Quebec Innovation Center. He is also the editor-in-chief of the journal Human Genetics. Hudson formerly served as assistant director of the Whitehead Institute/MIT Center for Genome Research and chaired the Science Committee of Genome Canada.


Jason Stajich has been elected president of the Open Bioinformatics Foundation, a non-profit organization that provides administrative support for BioPerl, BioJava, BioPython, and several other open source bioinformatics projects. OBF's board of directors elected Stajich, a graduate student in genetics at DukeUniversityand a core developer for the BioPerl project, to the position during the OBF's annual Bioinformatics Open Source Conference, June 23-24.

 

Stajich succeeds Ewan Birney of the European Bioinformatics Institute, who resigned after serving as president since the OBF was founded in 2001. Birney will remain on the OBF's board of directors as a board member at large, along with Steven Brenner of the Universityof California, Berkeley, another founding member of the OBF. Other OBF officers include Andrew Dalke, of Dalke Scientific Software, who serves as secretary; Chris Dagdigian of the BioTeam as treasurer; and Hilmar Lapp of the Novartis Research Foundation as parliamentarian.


Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.